Oruka Therapeutics
- Company typePublic
- Founded2024
- HeadquartersWaltham, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Oruka Therapeutics firmographics
Firmographics- Name
- Oruka Therapeutics
- Legal name
- Oruka Therapeutics, Inc.
- Website
- https://orukatx.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Oruka Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (62151)
- akta.pro primary industry
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
Keywords
Where Oruka Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Markets served
Oruka Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Oruka Therapeutics product offering
Product offeringCore offering
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing long-acting injectable monoclonal antibody therapeutics for chronic skin diseases, with lead candidates ORKA-001 (anti-IL-23p19) and ORKA-002 (anti-IL-17A/F) designed for dosing as infrequently as one or two times per year in moderate-to-severe plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The pipeline also includes preclinical ORKA-003 and a sequential induction-plus-maintenance combination regimen ORKA-021.
Product overview
Oruka Therapeutics is a clinical-stage biopharmaceutical company built around a single integrated antibody-engineering platform rather than multiple discrete software products; its offering is a pipeline portfolio of long-acting injectable monoclonal antibody therapeutics for chronic inflammatory skin diseases, organized as the core clinical assets ORKA-001 (IL-23p19 for moderate-to-severe plaque psoriasis) and ORKA-002 (IL-17A/F for psoriasis, psoriatic arthritis and hidradenitis suppurativa), the preclinical discovery program ORKA-003, and the combined induction-plus-maintenance regimen ORKA-021 that links ORKA-002 to ORKA-001, with the lead Halozyme Hypercon-formulated ORKA-001 program being advanced under a technology collaboration with Halozyme Therapeutics and originally discovered in partnership with Paragon Therapeutics.
Differentiator
Problem solved
Functional benefit
Brands
- ORKA-001: Lead clinical-stage monoclonal antibody candidate targeting IL-23p19 for plaque psoriasis, in Phase 2 (EVERLAST-A / EVERLAST-B), engineered for once- or twice-yearly dosing.
- ORKA-002
- ORKA-021
- ORKA-003
Products and services
- ORKA-001 Investigational high-potency, long-half-life humanized IgG1 monoclonal antibody targeting the IL-23p19 subunit, being developed as a maintenance therapy for moderate-to-severe plaque psoriasis and related inflammatory indications, designed to support dosing as infrequently as every six months.
- ORKA-002 Investigational humanized IgG1 monoclonal antibody that simultaneously binds and neutralizes IL-17A and IL-17F, being developed for moderate-to-severe plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa, with pharmacokinetics supporting once-every-three-month or less frequent subcutaneous dosing.
- ORKA-021 Investigational sequential combination regimen consisting of ORKA-002 (IL-17A/F) induction followed by ORKA-001 (IL-23p19) maintenance, intended to achieve rapid disease clearance and durable off-treatment remission in moderate-to-severe plaque psoriasis.
- ORKA-003 Undisclosed preclinical-stage discovery program being advanced through Oruka's antibody engineering platform alongside ORKA-001 and ORKA-002.
Companies that use Oruka Therapeutics
Customer profileIdeal customer profiles1 record
Oruka Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Oruka Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- Halozyme TherapeuticscoreHalozyme provides its Hypercon technology, which is licensed for use in ORKA-001 (an IL-23p19 inhibitor monoclonal antibody). The Hypercon platform enables extended half-life engineering, supporting a differentiated dosing profile (once or twice per year) for the lead IL-23p19 program.
- ARCA BiopharmaflagshipARCA Biopharma was the merger counterparty through which Oruka Therapeutics was formed. The reverse merger created the current Oruka Therapeutics entity focused on developing monoclonal antibody therapeutics for chronic skin diseases, including plaque psoriasis.
Recent moves7 records
Expansion highlights6 records
Oruka Therapeutics competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Markets Skyrizi (risankizumab), the leading IL-23p19 inhibitor in plaque psoriasis and psoriatic arthritis, which is the most direct incumbent comparator to ORKA-001 given shared mechanism.
- Johnson & Johnson (Innovative Medicine): Markets Tremfya (guselkumab, IL-23p19) and Stelara (ustekinumab, IL-12/23) in plaque psoriasis and related inflammatory indications, making it a direct head-to-head competitor to both ORKA-001 and ORKA-002.
- Novartis: Markets Cosentyx (secukinumab, IL-17A) across psoriasis, psoriatic arthritis, and hidradenitis suppurativa — exactly the indications Oruka is pursuing with ORKA-002.
- Eli Lilly: Markets Taltz (ixekizumab, IL-17A) for plaque psoriasis and related IL-17 indications, providing an incumbent benchmark for the ORKA-002 IL-17A/F program.
- UCB: Markets Bimzelx (bimekizumab), a dual IL-17A/F inhibitor approved in plaque psoriasis and other indications; the closest mechanism-comparable approved biologic to ORKA-002.
- Bristol-Myers Squibb: Markets Sotyktu (deucravacitinib), an oral TYK2 inhibitor approved for plaque psoriasis, representing a mechanistically distinct but indication-overlapping competitive threat to Oruka's injectable biologics.
Direct peers
- Sun Pharmaceutical Industries: Markets Ilumya/Tildrakizumab, an IL-23p19 inhibitor for moderate-to-severe plaque psoriasis, a direct mechanism competitor to ORKA-001 in the same indication.
Emerging players
- MoonLake Immunotherapeutics: Clinical-stage company developing sonelokimab, a nanobody targeting IL-17A/F/serum albumin for hidradenitis suppurativa and psoriasis; one of the most directly comparable emerging competitors to ORKA-002.
- Apogee Therapeutics: Clinical-stage immunology biotech developing long-acting biologics for atopic dermatitis and related inflammatory diseases; comparable emerging IL-pathway platform competitor with similar long-acting dosing strategy.
- AnaptysBio: Clinical-stage immunology company developing IL-36R and IL-23 pathway antibodies for inflammatory skin diseases; directly comparable immunology-focused pipeline approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Oruka Therapeutics social profiles
Digital presenceOruka Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oruka Therapeutics leadership team
Management profileNumber of profiles
Profiles15 records
Oruka Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oruka Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oruka Therapeutics
What does Oruka Therapeutics do?
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing long-acting injectable monoclonal antibody therapeutics for chronic skin diseases, with lead candidates ORKA-001 (anti-IL-23p19) and ORKA-002 (anti-IL-17A/F) designed for dosing as infrequently as one or two times per year in moderate-to-severe plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The pipeline also includes preclinical ORKA-003 and a sequential induction-plus-maintenance combination regimen ORKA-021.
Is Oruka Therapeutics a public or private company?
Oruka Therapeutics is a public company. It is classified as public and is currently operating.
When was Oruka Therapeutics founded?
Oruka Therapeutics was founded in 2024. It employs 101 to 250 people.
Where is Oruka Therapeutics based?
Oruka Therapeutics is headquartered in Waltham, United States, in the North America region.
Who are Oruka Therapeutics's main competitors?
Broad incumbents on record are AbbVie, Johnson & Johnson (Innovative Medicine), Novartis, Eli Lilly, UCB and Bristol-Myers Squibb. Sun Pharmaceutical Industries is listed as a direct peer. Emerging players are MoonLake Immunotherapeutics, Apogee Therapeutics and AnaptysBio.
Does Oruka Therapeutics have an API?
No public API is recorded for Oruka Therapeutics.
What industry is Oruka Therapeutics in?
Oruka Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 325414.